FDA Mevacor OTC Switch Answer: Signs Point To “Not Approvable”
This article was originally published in The Tan Sheet
Executive Summary
FDA appears to have issued a "not approvable" letter in response to J&J/Merck's application to switch the cholesterol-lowering drug Mevacor (lovastatin 20 mg) over the counter
You may also be interested in...
Study Bolsters Statin Myocardial Infarction Prevention Evidence
Use of statins and beta-blockers in individuals with no history of coronary disease may be correlated with a reduced risk of more serious cardiovascular events, a study in the Feb. 21 Annals of Internal Medicine finds
Study Bolsters Statin Myocardial Infarction Prevention Evidence
Use of statins and beta-blockers in individuals with no history of coronary disease may be correlated with a reduced risk of more serious cardiovascular events, a study in the Feb. 21 Annals of Internal Medicine finds
Study Bolsters Statin Myocardial Infarction Prevention Evidence
Use of statins and beta-blockers in individuals with no history of coronary disease may be correlated with a reduced risk of more serious cardiovascular events, a study in the Feb. 21 Annals of Internal Medicine finds